Sermorelin vs Tesamorelin + Ipamorelin
A side-by-side research comparison of Sermorelin and Tesamorelin + Ipamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Sermorelin | Tesamorelin + Ipamorelin |
|---|---|---|
| Full name | Sermorelin Acetate (GHRH 1-29) | Tesamorelin/Ipamorelin Combination |
| Category | Growth Hormone | Growth Hormone |
| Status | Previously FDA-approved (discontinued 2008) | Compounded combination |
| Mechanism | Binds GHRH receptors on anterior pituitary via cAMP-PKA pathway. Preserves natural feedback regulation and pulsatility unlike exogenous HGH. | Tesamorelin stimulates GH release by activating GHRH receptors on pituitary somatotrophs. Ipamorelin amplifies the pulse by acting on ghrelin/GHS receptors. Together they produce a synergistic "1+1=3" GH release while maintaining physiological pulsatility. |
| Molecular weight | 3,358 Da | Blend |
| Half-life | 10-20 minutes | Tesamorelin: ~26 min; Ipamorelin: ~2 hours. Combined peak GH at 30-60 min post-injection. |
| Bioavailability | Moderate (SubQ) | High (subcutaneous) |
| Typical dose | 200-300 mcg | Tesamorelin 1-2 mg + Ipamorelin 200-300 mcg |
| Frequency | Once daily before bed | Once daily (before bed) or twice daily |
| Route | Subcutaneous injection | Subcutaneous injection |
Sermorelin reported benefits
- Natural GH pulsatility preserved
- Improved sleep quality
- Body composition improvement
- Skin elasticity
- Long safety record
Tesamorelin + Ipamorelin reported benefits
- Significant fat loss (especially visceral/abdominal)
- Lean muscle gains
- Improved sleep quality
- Enhanced recovery
- Anti-aging effects
- Better body composition without exogenous HGH side effects
Related comparisons
Research and educational reference only. Not medical advice.